^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Myelodysplastic Syndrome

    1d
    CR108485: A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS (clinicaltrials.gov)
    P1, N=114, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed
    Trial completion
    |
    onametostat (JNJ-64619178)
    1d
    Assessing ginger (6-Shogaol) in improving blood markers (cytopenias) of patients with lower risk Myelodysplastic Syndromes – a pilot clinical trial (ACTRN12623001349639)
    P1/2, N=30, Completed, Southern Cross University | Recruiting --> Completed
    Trial completion
    2d
    Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome (clinicaltrials.gov)
    P1/2, N=52, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Vanflyta (quizartinib) • Vyxeos (cytarabine/daunorubicin liposomal formulation)
    2d
    Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (clinicaltrials.gov)
    P1/2, N=80, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    cytarabine • Vanflyta (quizartinib) • idarubicin hydrochloride • cladribine • Starasid (cytarabine ocfosfate)
    2d
    Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant (clinicaltrials.gov)
    P1/2, N=16, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    2d
    DarbeLus: Luspatercept + Darbepoetin in MDS (clinicaltrials.gov)
    P2, N=60, Recruiting, Yale University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Reblozyl (luspatercept-aamt) • Aranesp (darbepoetin alfa)
    2d
    NCI-2019-08946: CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old (clinicaltrials.gov)
    P2, N=21, Active, not recruiting, Roswell Park Cancer Institute | Suspended --> Active, not recruiting | N=46 --> 21 | Trial primary completion date: Jan 2027 --> Jun 2025
    Enrollment closed • Enrollment change • Trial primary completion date
    |
    Vyxeos (cytarabine/daunorubicin liposomal formulation)
    3d
    Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm (clinicaltrials.gov)
    P2, N=132, Active, not recruiting, National Cancer Institute (NCI) | Suspended --> Active, not recruiting
    Enrollment closed
    |
    Venclexta (venetoclax) • Inqovi (decitabine/cedazuridine)
    3d
    The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas (clinicaltrials.gov)
    P2, N=27, Not yet recruiting, Mayo Clinic
    New P2 trial
    4d
    VEXAS syndrome mimicking relapsing polychondritis: A case report (PubMed, Beijing Da Xue Xue Bao Yi Xue Ban)
    Notwithstanding substantial concerns about thrombotic risk due to positive phospholipid antibodies in the context of ruxolitinib treatment, thrombotic events were avoided with patient compliance to low-dose aspirin therapy. This case highlighted that the male patients aged over 50 years presenting with chondritis, refractory autoinflammatory manifestations, and/or unexplained hematological abnormalities, clinicians should consider bone marrow evaluation and UBA1 gene testing to promptly identify VEXAS syndrome, enabling early personalized treatment and improved outcomes.
    Journal
    |
    IL6 (Interleukin 6) • CRP (C-reactive protein)
    |
    Jakafi (ruxolitinib) • aspirin
    4d
    Triptolide combined with arsenic trioxide induces apoptosis of myelodysplastic syndrome cells by inhibiting the NF-κB signaling pathway. (PubMed, Medicine (Baltimore))
    The combined impact of TL and ATO amplifies the expression of p65 within the canonical NF-κB signaling pathway, while inhibiting the expression of IkBα, p52, and RelB in the noncanonical pathway. The combination effect of TL and ATO markedly suppresses the proliferation of MDS cells and induces apoptosis collaboratively, which potentially occurs through a mechanism by inhibiting the NF-κB signaling pathway.
    Journal • PARP Biomarker • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • ANXA5 (Annexin A5) • RELA (RELA Proto-Oncogene)
    |
    arsenic trioxide
    4d
    FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=33, Not yet recruiting, Montefiore Medical Center
    New P1 trial
    |
    Venclexta (venetoclax) • decitabine • camibirstat (FHD-286)